Posttransplantation Lymphoproliferative Disorder

  • Aamir Ehsan
  • Jennifer L. Herrick
Part of the Molecular Pathology Library book series (MPLB, volume 1)


Lymphoproliferative disorders are known complications of congenital and acquired immunodeficiency and/or iatrogenic-induced immunosuppression. A lymphoplasmacytic proliferation or lymphoma developing as a consequence of continuous iatrogenic immunosuppression following solid organ transplantation and hematopoietic stem cell transplantation (HSCT) is called posttransplantation lymphoproliferative disorder (PTLD). Posttransplantation lymphoproliferative disorders are a morphologically and clinically heterogenous group of disorders, many of which are associated with the Epstein-Barr virus (EBV). Morphologically the spectrum ranges from polyclonal lymphoplasmacytic proliferations resembling infectious mononucleosis to frankly neoplastic lymphomas. These lymphomas are commonly EBV positive B cell and less commonly EBV negative (B or T cell) in origin. Clinically, some of these disorders regress after reduction of the immunosuppressive regimen, and others progress to serious and potentially fatal lymphomas requiring chemotherapy.


Hematopoietic Stem Cell Transplantation Germinal Center Lymphoproliferative Disorder Solid Organ Transplant Recipient Posttransplantation Lymphoproliferative Disorder 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Penn I, Hammon W, Brettschneider L, et al. Malignant lymphomas in transplantation patients. Transplant Proc 1969;1:106.PubMedGoogle Scholar
  2. 2.
    Frizerra G, Hanto DW, Gajl-Peczalska KJ, et al. Polymorphic diffuse B-cell hyperplasia and lymphomas is renal transplant recipients. Cancer Res 1981;41:4262–4279.Google Scholar
  3. 3.
    Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of PTLDs occurring the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988;133:173–192.PubMedGoogle Scholar
  4. 4.
    Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of post transplantation lymphoproliferative disorders. Blood 1995;85:552–565.PubMedGoogle Scholar
  5. 5.
    Harris NL, Swerdlow SH, Frizerra G, et al. Post transplant lymphoproliferative disorders in Tumours of Haematopoietic and Lymphoid Tissues. In Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. WHO Classification of Tumours. Lyon, France: IARC Press; 2001:264–269.Google Scholar
  6. 6.
    Levine SM, Angel L, Anzueto A, et al. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipient. Chest 1999;116:1273–1277.CrossRefPubMedGoogle Scholar
  7. 7.
    Montone KT, Litzsky LA, Wurster A, et al. Analysis of Epstein-Barr virus associated posttransplantation lymphoproliferative disorder after lung transplantation. Surgery 1996;119:544–551.CrossRefPubMedGoogle Scholar
  8. 8.
    Shapiro R, Nalesnik M, McCauley J, et al. PTLD in adult and pediatric renal transplant recipients receiving tacrolimus based immunosuppression. Transplantation 1999;68:1851–1854.CrossRefPubMedGoogle Scholar
  9. 9.
    Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor to posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995;14:214–221.PubMedGoogle Scholar
  10. 10.
    Newell KA, Alonso EM, Kelly SM. Association between liver transplantation for Langerhans cell histiocytosis, rejection and development of PTLD in children. J Pediatr 1999;131:98–103.Google Scholar
  11. 11.
    Ho M, Jaffe R, Miller G. The frequency of EBV infection and associated lymphoproliferative disease after transplantation and its manifestations in children. Transplantation 1988;45:719–724.CrossRefPubMedGoogle Scholar
  12. 12.
    Shpilberg O, Wilson J, Whiteside TL. Pre-transplant immunological profile and risk factor analysis of PTLD development: the results of a nested matched case-control study: The University of Pittsburg PTLD study group. Leuk Lymphoma 1999;36:109–113.CrossRefPubMedGoogle Scholar
  13. 13.
    Levine SM, Angel L, Anzueto A, et al. A low incidence of PTLD in 109 lung transplant recipient. Chest 1999;116:1273–1277.CrossRefPubMedGoogle Scholar
  14. 14.
    Aris RM, Maia DM, Neuringer IP, et al. PTLD in EBV naïve lung transplant recipients. Am J Respir Crit Care Med 1996;154:1712–1717.PubMedGoogle Scholar
  15. 15.
    Montone KT, Litzky LA, Wurster A, et al. Analysis of EBV associated PTLD after lung transplantation. Surgery 1996;119:544–551.CrossRefPubMedGoogle Scholar
  16. 16.
    Cohen AH, Sweet SC, Mendeloff E, et al. High incidence of PTLD in pediatric patients with cystic fibrosis. Am J Resp Crit Care Med 2000;161:1252–1255.PubMedGoogle Scholar
  17. 17.
    Ferry JA, Jacobson JO, Conti D, et al. Lymphoproliferative disorders and hematologic malignancies following organ transplantation. Mod Pathol 1989;2:583–592.PubMedGoogle Scholar
  18. 18.
    Leblond V, Davi F, Charlotte F, et al. Post transplant lymphoproliferative disorders not associated with EpsteinBarr virus: a distinct entity? J Clin Oncol 1998;16:2052–2059.PubMedGoogle Scholar
  19. 19.
    Nelson BP, Nalesnik MA, Bahler DW, et al. Epstein-Barr virus negative post transplant lymphoproliferative disorders: a distinct entity? Am J Surg Pathol 2000;24:375–385.CrossRefPubMedGoogle Scholar
  20. 20.
    Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet 1964;15:702–703.CrossRefGoogle Scholar
  21. 21.
    Babcock GJ, Decker LL, Volk M, et al. EBV persistence in memory B cells in-vivo. Immunity 1998;9:395–404.CrossRefPubMedGoogle Scholar
  22. 22.
    Joseph AM, Babcock GJ, Thorley-Lawson DA. EBV persistence involves strict selection of latently infected B cells. J Immunol 2000;165:2975–2981.PubMedGoogle Scholar
  23. 23.
    Kieff E, Rickinson AB. EBV and its replication. In Knipe DM, Howley PM, eds. Fields Virology, 4th ed, vol 2. Philadelphia: Lippincott Williams & Wilkins; 2001:2511–2574.Google Scholar
  24. 24.
    Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985;43:831–840.CrossRefPubMedGoogle Scholar
  25. 25.
    Kulwichit W, Edwards RH, Davenport EM, et al. Expression of the EBV LMP-1 induces B-cell lymphoma in transgenic mice. Proc Natl Acad Sci USA 1998;95:11963–11968.CrossRefPubMedGoogle Scholar
  26. 26.
    Henderson S, Rowe M, Gregory C, et al. Induction of bcl-2 expression by EBV LMP-1 protects infected B cells form programmed cell death. Cell 1991;65:1107–1115.CrossRefPubMedGoogle Scholar
  27. 27.
    Laherty CD, Hu HM, Opipari AW, et al. The EBV LMP-1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem 1992;267:24157–24160.PubMedGoogle Scholar
  28. 28.
    Miller CL, Burkhardt AL, Lee JH, et al. Integral membrane protein 2 of EBV regulates reactivation from latency through dominant negative effects on protein tyrosinase kinases. Immunity 1995;2:155–166.CrossRefPubMedGoogle Scholar
  29. 29.
    Lam KP, Kuhn R, Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 1997;90:1073–1083.CrossRefPubMedGoogle Scholar
  30. 30.
    Caldwell RG, Wilson JB, Anderson SJ, et al. EBV LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 1998;9:405–411.CrossRefPubMedGoogle Scholar
  31. 31.
    Casola S, Otipoby KL, Alimzhanov M, et al. B cell receptor signal strength determines B cell fate. Nat Immunol 2004;5:317–327.CrossRefPubMedGoogle Scholar
  32. 32.
    Thorley-Lawson DA, Gross A. Persistence of the EBV and the origins of associated lymphomas. N Engl J Med 2004;350(13):1328–1337.CrossRefPubMedGoogle Scholar
  33. 33.
    Babcock GJ, Decker LL, Volk M, et al. EBV persistence in memory B cells in-vivo. Immunity 1998;9:395–404.CrossRefPubMedGoogle Scholar
  34. 34.
    Cohen JI. EBV Infection. N Eng J Med 2000;343(7):481–492.CrossRefGoogle Scholar
  35. 35.
    Moore KW, Vieira P, Fiorentinio DF, et al. Homology of cytokine synthesis inhibitory factor (IL-10) to the EBV gene BCRF1. Science 1990;248:1230–1234.CrossRefPubMedGoogle Scholar
  36. 36.
    Hsu D-H, de Waal Malefyt R, Fiorentino DF, et al. Expression of IL-10 activity by EBV protein BCRF1. Science 1990;250:830–832.CrossRefPubMedGoogle Scholar
  37. 37.
    Cohen JI, Lekstrom K. EBV BARF1 protein is dispensable for B-cell transformation and inhibits alpha interferon secretion form mononuclear cells. J Virol 1999;73:7627–7632.PubMedGoogle Scholar
  38. 38.
    Henderson S, Huen D, Rowe M, et al. EBV coded BHRF1 protein, a viral homolog of bcl-2, protects human B cells form programmed cell death. Proc Natl Acad Sci USA 1993;90:8479–8483.CrossRefPubMedGoogle Scholar
  39. 39.
    Levitskaya J, Shapiro A, Leonchiks A, et al. Inhibition of ubiquitin/proteosome-dependent protein degradation by the Gly-Ala repeat domain of the EBAN-1. Proc Natl Acad Sci USA 1997;94:12616–12621.CrossRefPubMedGoogle Scholar
  40. 40.
    Rooney CM, Rowe M, Wallace LE, et al. EBV positive Burkitt’s lymphoma cells not recognized by virus-specific T-cell surveillance. Nature 1985;317:629–631.CrossRefPubMedGoogle Scholar
  41. 41.
    Gregory CD, Muraay RJ Edwards CF, et al. Down regulation of cell adhesion molecules LFA-3 and ICAM-1 in EBV+ Burkitt’s lymphoma underlies tumor cell escape form virus-specific T cell surveillance. J Exp Med 1988;167:1811–1824.CrossRefPubMedGoogle Scholar
  42. 42.
    Rowe M, Khanna R, Jacob CA, et al. Restoration of endogenous antigen processing in Burkitt’s lymphoma cells by EBV LMP-1: coordinate up regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol 1995;25:1374–1384.CrossRefPubMedGoogle Scholar
  43. 43.
    DeCampos-Lima PO, Levitsky B, Brooks J, et al. T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in EBV isolates for highly A11-positive populations by selective mutation of anchor residues. J Exp Med 1994;179:1297–1305.CrossRefGoogle Scholar
  44. 44.
    Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of PTLDs. Blood 1995;85:552–565.PubMedGoogle Scholar
  45. 45.
    Cesarman E, Chadburn A, Liu YF, et al. BCL-6 gene mutations in PTLD predict response to therapy and clinical outcome. Blood 1998;92:2294–2302.PubMedGoogle Scholar
  46. 46.
    Chadburn A, Chen JM, Hsu DT, et al. The morphologic and molecular genetic categories of PTLDs are clinically relevant. Cancer 1998;82:1978–1987.CrossRefPubMedGoogle Scholar
  47. 47.
    Muller-Hermelink HK, Greiner A. Molecular analysis of human immunoglobulin heavy chain variable genes (IgVH) in normal and malignant B cells. Am J Pathol 1998;153:1341–1346.PubMedGoogle Scholar
  48. 48.
    Kuppers R, Klein U, Hansman ML, et al. Cellular origin of human B-cell lymphoma. N Engl J Med 1999;341:1520–1529.CrossRefPubMedGoogle Scholar
  49. 49.
    Stevenson FK, Sahota SS, Ottensmeier CH, et al. The occurrence and significance of V gene mutations in B cell-derived human malignancy. Adv Cancer Res 2001;83:81–116.CrossRefPubMedGoogle Scholar
  50. 50.
    Pasqualucci L, Migliazza A, Fracchiolla N, et al. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc Natl Acad Sci USA 1998;95:11816–11821.CrossRefPubMedGoogle Scholar
  51. 51.
    Shen HM, Peters A, Baron B, et al. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutations of Ig genes. Science 1998;280:1750–1752.CrossRefPubMedGoogle Scholar
  52. 52.
    Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.CrossRefPubMedGoogle Scholar
  53. 53.
    Catoretti G, Chang C-C, Cechova C, et al. BCL-6 protein is expressed in germinal-center B cells. Blood 1995;86:45–53.Google Scholar
  54. 54.
    Falini B, Fizzotti M, Pucciarini A, et al. A monoclonal antibody (MUM1p) detects expression of the MUMI/IRF1 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000;95:2084–2092.PubMedGoogle Scholar
  55. 55.
    Carbone A, Gloghini A, Larocca LM, et al. Expression profile of MUMi/IRF-4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood 2001;97:744–751.CrossRefPubMedGoogle Scholar
  56. 56.
    Capello D, Cerri M, Muti G, et al. Molecular histogenesis of PTLDs. Blood 2003;102(10):3775–3785.CrossRefPubMedGoogle Scholar
  57. 57.
    Novoa-Takara L, Perkins SL, Qi D, et al. Histogenetic phenotypes of B cells in PTLDs by immunohistochemical analysis correlate with transplant type. Solid organ vs hematopoietic stem cell transplantation. Am J Clin Pathol 2005;123:104–112.CrossRefPubMedGoogle Scholar
  58. 58.
    Smir BN, Hauke RJ, Bierman PJ, et al. Molecular epidemiology of deletions and mutations of the LMP1 oncogene of the EBV in PTLD. Lab Invest 1996;75(4):575–588.PubMedGoogle Scholar
  59. 59.
    Scheinfeld AG, Nador RG, Cesarman E, et al. EBV LMP-1 oncogene deletion in PTLDs. Am J Pathol 1997;151(3):805–812.PubMedGoogle Scholar
  60. 60.
    Carpentier L, Tapiero B, Alvarez F, et al. EBV EA serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of PTLD. J Infect Dis 2003;188:1853–1863.CrossRefPubMedGoogle Scholar
  61. 61.
    Henle W, Henle G. EBV specific serology in immunologically compromised individuals. Cancer Res 1981;41:4222–4225.PubMedGoogle Scholar
  62. 62.
    Green M, Reyes J, Weber S, et al. The role of viral load in the diagnosis, management and possible prevention of EBV associated PTLD following solid organ transplantation. Curr Opin Organ Transplant 1999;4:292–296.CrossRefGoogle Scholar
  63. 63.
    Tsai D, Nearey M, Hardy C, et al. Use of EBV PCR for the diagnosis and monitoring of PTLD in adult solid organ transplant recipients. Am J Transplant 2002;2:946–954.CrossRefPubMedGoogle Scholar
  64. 64.
    Green M, Caccuarelli TV, Mazareigos GV, et al. Serial measurements of EBV load in peripheral blood in pediatric liver transplant recipient for PTLD. Transplantation 1998;66:1641–1644.CrossRefPubMedGoogle Scholar
  65. 65.
    Wagner HJ, Wessel M, Jabs W, et al. Patients at the risk for development of PTLD: plasma versus peripheral blood mononuclear cells as material for quantification of EBV loads by using real-time quantitative PCR. Transplantation 2001;72(6):1012–1019.CrossRefPubMedGoogle Scholar
  66. 66.
    Cockfiled SM. Identifying the patient at risk for PTLD. Transplant Infect Dis 2001;3:70–78.CrossRefGoogle Scholar
  67. 67.
    Preiksaitis JK. New developments in the diagnosis and management of PTLDs in solid organ transplant recipients. Clin Infect Dis 2004;39(7):1016–1023.CrossRefPubMedGoogle Scholar
  68. 68.
    Penn I. The role of immunosuppression in lymphoma formation. Springer Semin Immunopathol 1998;20(34):343–355.CrossRefPubMedGoogle Scholar
  69. 69.
    Oertel S, Trappe RU, Zeidler K, et al. Epstein-Barr viral load in whole blood of adults with post transplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. Ann Hematol 2006;85(7):478–484.CrossRefPubMedGoogle Scholar
  70. 70.
    Orjuela M, Gross TG, Cheung YK, et al. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, rituximab) in patients with PTLD following solid organ transplantation. Clin Cancer Res 2003;9(10 Pt 2):3945S–3952S.PubMedGoogle Scholar
  71. 71.
    Penn I. Immunosuppression—a contributory factor in lymphoma formation. Clin Transplant 1992;6:214.Google Scholar
  72. 72.
    Benkerrow MD, Randy A, Fischer A. Therapy for transplant-related lymphoproliferative diseases. Hemat Oncol Clin North Am 1993;7:467.Google Scholar
  73. 73.
    Muti G, Cantoni S, Oreste P, et al. PTLDs: improved outcome after clinico-pathologically tailored treatment. Haematologica 2002;87(1):67–77.PubMedGoogle Scholar
  74. 74.
    McCarthy M, Ramage J, McNair A, et al. The clinical diversity and role of chemotherapy in lymphoproliferative disorder in liver transplant recipients. J Hepatol 1997;27(6):1015–1021.CrossRefPubMedGoogle Scholar
  75. 75.
    Milpied N, Vasseur B, Parquet N, et al. Humanized anti-C20 monoclonal antibody (Rituximab) in post transplant B lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000;11(Suppl 1):113–116.CrossRefPubMedGoogle Scholar
  76. 76.
    Ganne V, Siddiqi N, Kamaplath B, et al. Humanized anti-C20 monoclonal antibody (rituximab) in PTLD. Clin Transplant 2003;17(5):417–422.CrossRefPubMedGoogle Scholar
  77. 77.
    Ifthikharuddin JJ, Mieles LA, Rosenblatt JD, et al. Coexpression in PTLD; treatment with rituximab. Am J Hematol 2000;65(2):171–173.CrossRefPubMedGoogle Scholar
  78. 78.
    Reynaud-Gaubert M, Stoppa AM, Gaubert J, et al. Anti-CD20 monoclonal antibody therapy in EBV associated B-cell lymphoma following lung transplantation. J Heart Lung Transplant 2000;19(5):492–495.CrossRefPubMedGoogle Scholar
  79. 79.
    Rooney CM, Smith CA, Ng CY, et al. Use of gene modified virus specific T lymphocytes to control EBV related lymphoproliferations. Lancet 1995;345(8941):9–13.CrossRefPubMedGoogle Scholar
  80. 80.
    Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of EBV induced lymphoma in allogeneic transplant recipients. Blood 1998;92(5):1549–1555.PubMedGoogle Scholar
  81. 81.
    Wagner HJ, Cheng YC, Huls MH, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004;103(10):3979–3981.CrossRefPubMedGoogle Scholar
  82. 82.
    Liu Z, Savoldo B, Huls H, et al. EBV specific cytotoxic T lymphocytes for the prevention and treatment of EBV associated post transplant lymphomas. Recent Results Cancer Res 2002;159:123–133.PubMedGoogle Scholar
  83. 83.
    Heslop HE, Ng CY, Li C, et al. Long term restoration of immunity against EBV infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2(5):551–555.CrossRefPubMedGoogle Scholar
  84. 84.
    Haque T, Wilkeie GM, Taylor C, et al. Treatment of EBV positive PTLD with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002;360(9331):436–442.CrossRefPubMedGoogle Scholar
  85. 85.
    Gottschalk S, Rooney CM, Heslop HE. Post transplant lymphoproliferative disorders. Annu Rev Med 2005;56:29–44.CrossRefPubMedGoogle Scholar
  86. 86.
    Comoli P, Labirio M, Basso S, et al. Infusion of autologous EBV specific cytotoxic T cells for prevention of EBV related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002;99(7):2592–2598.CrossRefPubMedGoogle Scholar
  87. 87.
    Feng S, Buell JF, Chari RS, et al. Tumors and transplantation. The 2003 third annual ASTS state of the art winter symposium. Am J Transplant 2003;3(12):1481–1487.CrossRefPubMedGoogle Scholar
  88. 88.
    Leblond V, Choquet S. Lymphoproliferative disorders after liver transplantation. J Hepatol 2004;40(5):728–735.CrossRefPubMedGoogle Scholar
  89. 89.
    Scheenstra R, Verschuuren EA, de Hann A, et al. The value of prospective monitoring of EBV DNA in blood samples of pediatric liver transplant recipients. Transplant Infect Dis 2004;6(1):15–22.CrossRefGoogle Scholar
  90. 90.
    Green M, Michaels MG, Webber SA, et al. The management of EBV associated PTLD in pediatric solid organ transplant recipients. Pediatr Transplant 1999;3(4):271–281.CrossRefPubMedGoogle Scholar
  91. 91.
    Davis CL. The antiviral prophylaxis of PTLD. Springer Semin Immunopathol 1998;20(34):437–453.CrossRefPubMedGoogle Scholar
  92. 92.
    Gu SY, Huang TM, Ruan L, et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand 1995;84:171–177.PubMedGoogle Scholar
  93. 93.
    Dotti G, Fiocchi R, Motta T, et al. EBV negative lymphoproliferative disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation 2000;69(5):827–833.CrossRefPubMedGoogle Scholar
  94. 94.
    Ghobrial IM, Habermann TM, Maurer MJ, et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol 2005;23(30):7574–7582.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Aamir Ehsan
    • 1
  • Jennifer L. Herrick
    • 2
  1. 1.University of Texas Health Science Center at San Antonio and Audie L. Murphy VA Medical CenterSan AntonioUSA
  2. 2.Department of PathologyUniversity of Texas Health Science Center at San AntonioSan AntonioUSA

Personalised recommendations